Starting treatment: latest news

Starting treatment resources

Starting treatment features

Starting treatment in your own words

Starting treatment news from aidsmap

More news

Starting treatment news selected from other sources

  • Men Who Have Sex With Men Getting Treatment Sooner

    Long-term trends indicate that European men who have sex with men are seeking treatment for HIV at earlier stages of their disease, researchers reported here.

    25 July 2014 | MedPage Today
  • Option B+: In obstacle courses to lifelong antiretroviral treatment, hurdles are higher for pregnant women, study says

    Work conflicts, hidden HIV status, and bad treatment by staff are among the hurdles keeping women living with HIV from continuing antiretroviral treatment for life following childbirth, according to a article published last month ahead of print in the Journal of Acquired Immune Deficiency Syndromes.

    09 July 2014 | Science Speaks
  • New ARV prescribing guidelines for London (2014)

    The guidelines are the result of a therapeutic tender, which encourages drug manufacturers to offer volume discounts for different stages of the treatment pathway, for example, for preferred use in first-line, second-line and multiple resistant treatment.

    01 July 2014 | HIV i-Base
  • Dolutegravir in HIV-1 infection: Added benefit in adult patients

    The German Institute for Quality and Efficiency in Health Care (IQWiG) has determined that the new integrase inhibitor drug dolutegravir (Tivicay ®) is of considerable added benefit to treatment-naive patients in comparison with current first-line therapies, and some added benefit to patients who already need to take an integrase inhibitor.

    19 June 2014 | Science Daily
  • First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily formulation of raltegravir (Isentress)

    Merck (MSD) today announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS® (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults. Raltegravir combines high potency with low toxicity but its more widespread use has been held back by its needing to be taken twice a day.

    06 June 2014 | Merck
  • Five-drug ART has no advantage over three drugs for early HIV

    Starting antiretroviral therapy (ART) with five drugs instead of three offered no virologic or immunologic advantage in people with early HIV infection, according to results of a randomized trial.

    04 June 2014 | International AIDS Society
  • Ethiopia: HIV patient nutrition more vital than once assumed

    Researchers have shown that a dietary supplement given during the first months of HIV treatment significantly improves the general condition of patients. Their results are published in the journal BMJ.

    15 May 2014 | University of Copenhagen (press release)
  • Why some people don’t want to start HIV treatment

    Researchers in the European Union and Australia conducted research into perceived barriers to starting ART. A primary barrier for HIV-positive people is not feeling sufficiently unwell or having symptoms. Doctors delayed initiation of ART when they perceived patients to be suffering from depression, if there was substance use or if they believed that patients did not understand the need to adhere to HIV medicines.

    19 February 2014 | CATIE
  • Antiretroviral treatment French guidelines 2013: economics influencing science

    In the new French guidelines, economic considerations significantly influence and, in some instances, take precedence over the scientific evidence, leading to guidelines that are significantly different from those of other national and international committees.

    27 January 2014 | Journal of Antimicrobial Chemotherapy
  • Perry N. Halkitis: Does Treatment As Prevention Care for the HIV-positive?

    I would like to think that those advocating treatment as prevention ultimately have the health of HIV-positive individuals in mind first and foremost. But my immersion into the UK system this last month has led me to wonder about the motivation that underlies this approach.

    22 January 2014 | Huffington Post
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.